FR2783606A1 - Production of therapeutic coagulants or anticoagulants using electromagnetic signals characteristic of these properties - Google Patents

Abstract

An inactive substance, such as water, water and ethanol, or homeopathic granules, is given coagulant or anticoagulant properties, by applying a specific electromagnetic field to the substance. The field used is characteristic of a substance containing calcium ions for a coagulant, or heparin for an anticoagulant. Independent claims are included for systems to carry out the process and test its efficacy, and the substance produced. Electrical signals are obtained from a sample (1) contained in a glass cell (3) adjacent to an electrical, magnetic or electromagnetic signal emitter (4). After passing through the sample the transformed signal is received by a transducer (6), and relayed (9') to a computer.

Description

Method and system for producing a substance or signal having an effect

  coagulant or anticoagulant. Therapeutic applications of said

substance or said signal.

  The present invention relates to a method and a system for producing a substance or signal, notably an electrical signal, having a coagulating or anticoagulant effect. The invention also relates to such a substance or such a signal and to their therapeutic effects. The invention also relates to a method and a system for testing the coagulating effect.

  or anticoagulant of a substance or signal.

  We know, since the research work of Mr. Jacques Benveniste, in particular those described in patent application WO 94/17406 published on August 4, 1994, that we can capture from a biological element and / or

  active chemical such as a chemical compound, cell or micro-

  organism, or from a substance containing this active element, an "electromagnetic signal characteristic of the biological and / or chemical activity or of the biological and / or chemical behavior" of said

  substance and / or said active element contained in said substance.

  We also know that it is possible to transfer, in particular by means

  of a transducer, such an electromagnetic signal into an electrical signal.

  In the remainder of the text, the expression “electrical signal characteristic of the biological and / or chemical activity or of the biological and / or chemical behavior of a substance or of an active element contained in said substance” is also understood to mean any derived electrical signal by scanning and / or signal processing. In this expression, "characteristic" is used in the sense that the physical parameters of the electrical signal are specific to the substance or to the active element contained in said substance. In other words, the application of this electrical signal, via a transducer, to a biological control system makes it possible: (i) to induce a biological and / or chemical activity on said biological control system in relation to that of the substance d origin or active element it contains, (ii) reveal a characteristic of the active substance or element

  that it contains, at the origin of said electrical signal.

  Patent application WO 94/17406, published on August 4, 1994, describes a method and a device for picking up "an electromagnetic signal characteristic of a biological and / or chemical activity or of a biological and / or chemical behavior" from a biological and / or active chemical element such as a chemical compound, a cell or a microorganism, or from a substance containing this active element such as a purified preparation, a biological sample, a living being. The inventors have since discovered that it is possible to improve the quality of the electromagnetic signal picked up as well as the reliability of the process for producing this signal and that it is therefore possible to produce

  a characteristic electrical signal capable of industrial applications.

  These developments have been described in the French application FR 98 12 058 filed on September 23, 1998. As necessary, the elements of this application, not yet published to date, useful for understanding the present invention, will be extracted and inserted in the

this request.

  Method and system according to the invention for producing a substance

  having a coagulant or anticoagulant effect.

  The process according to the invention for producing a substance having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular of

  heparin, comprises at least the following stages.

  The purpose of stage I is to transform the electromagnetic field originating from said source substance into a signal, in particular a signal

3 2783606

  electrical characteristic, by means of a receiving transducer-receiver

said electromagnetic field.

  The purpose of step 2 is to apply to a receiving substance, in particular water or a water-ethanol mixture or homeopathic granules, said signal coming from said transducer-receiver, by means of a transducer-transmitter. It is found that after the above-defined treatment, the receiving substance,

  initially inactive, has coagulating or anticoagulant activity.

  The receptor substance thus treated will hereinafter be called the "substance

processed ".

  The concentration of the active elements in the source substance, in particular the concentration of Ca ++ ions having a coagulating effect or of heparin having an anticoagulant effect, can be of the order of 11tM. It can also be very low and reach 10-14 M. The source substance can also consist of homeopathic products, diluted if necessary in water to

injectable preparation.

  Preferably, to transform the electromagnetic field originating from said source substance into an electrical signal - the said source substance is placed in an area subjected to an excitation field of an electrical, magnetic and / or electromagnetic nature and, - the resulting fields are transformed of the interaction of the excitation field and said source substance into an electrical signal, at the

  by means of a transducer-receiver capturing said resulting fields.

  The system according to the invention for producing a substance having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ′ ions, or anticoagulant, in particular of

  heparin, comprises at least the elements defined below.

  A transducer-receiver receives the electromagnetic field from

4 2783606

  of said source substance. Said transducer-receiver transforms said

  electromagnetic field into a signal, especially an electrical signal.

  A transducer-transmitter allows to apply the signal coming from said transducer-receiver to a receiving substance, in particular water or a water-ethanol mixture or homeopathic granules. After the treatment implemented by the system defined above, the receptor substance, initially inactive, exhibits coagulating activity

or anticoagulant.

  Preferably, the system according to the invention further comprises an emitter generating an excitation field of an electrical, magnetic and / or electromagnetic nature in an area where said source substance is located. A transducer-receiver, receiving the fields resulting from the interaction of said excitation field and said source substance, transmits said

  fields resulting in a signal, in particular an electrical signal.

  Substance according to the invention having a coagulating or anticoagulant effect The invention also relates to a substance having a coagulating or

  anticoagulant. Said substance, such as water or a water mixture

  ethanol or homeopathic granules, is characterized in that it has been treated by means of an electrical or electromagnetic signal originating from a source substance having coagulating effects, in particular

  Ca ++ ions, or anticoagulant, in particular heparin.

  The invention also relates to the therapeutic applications of such a substance. The substance according to the invention can be used in the treatment of thromboembolic disease. It can also be used

  to perform coagulation exploration tests.

  Method according to the invention for testing the coagulant or anticoagulant effect of a substance The invention also relates to a method for testing a substance having a coagulating effect, notanmunent of Ca ++ ions, or anticoagulant, in particular heparin. The method includes at least the following steps. The purpose of step 1 is to transfer the electromagnetic field originating from said substance, into a signal, in particular an electrical signal, by means of a transducer-receiver sensing said electromagnetic field. The purpose of step 2 is to apply to a sensitive biological system,

  directly or indirectly, said signal coming from said transducer-

  receiver. Preferably, according to the invention to transform the electromagnetic field originating from said substance into an electrical signal, said substance is placed in an area subjected to an excitation field of an electrical, magnetic and / or electromagnetic nature, - the resulting fields are transformed of the interaction of the excitation field and said source substance into an electrical signal, at the

  by means of a transducer-receiver capturing said resulting fields.

  Advantageously, the sensitive biological system can be blood or

  plasma to which said signal is applied by means of a transducer-

  transmitter. It is also advantageous to use plasma rich in

platelets.

  Advantageously, according to another alternative embodiment, the sensitive biological system is an arimnal, in particular a rabbit, to which a substance, in particular water, is administered, in particular under the tongue,

  processed by said signal by means of a transducer-transmitter.

  The method according to the invention for testing the coagulant or anticoagulant effect of a substance can be applied to the control of production of homeopathic products. Method and system according to the invention for producing a signal having a

coagulant or anticoagulant effect.

  The method according to the invention for producing a signal, in particular an electrical or electromagnetic signal, having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin , comprises at least the step of transforming the electromagnetic field originating from said source substance, into a signal, in particular an electrical signal, by means of a transducer-receiver sensing said electromagnetic field. Preferably, in order to transform the electromagnetic field originating from said source substance into an electrical signal: - said source substance is placed in an area subjected to an excitation field of an electrical, magnetic and / or electromagnetic nature, - the fields resulting from the interaction of the excitation field and the source substance, into a signal, in particular an electrical signal, by means of a transducer-receiver sensing said resulting fields. Preferably also, the method according to the invention for producing a signal, in particular an electrical or electromagnetic signal, having a coagulant or anticoagulant effect, further comprises the step of controlling

  the correlations between a palrt, the signal coming from said transducer-

  receptor and on the other hand, the coagulating or anticoagulant activity of said source substance, by applying, directly or indirectly, said signal to a biological control system and by verifying that said biological control system reacts in accordance with the coagulating activity or

  anticoagulant of the source substance from which the signal comes.

  Advantageously, the biological control system is blood or

  plasma to which said signal is applied by means of a transducer-

  transmitter. It is also advantageous to use plasma rich in

7 2783606

  platelets. Advantageously, in another alternative embodiment, the biological control system is an animal, in particular a rabbit, to which a substance, in particular water, which is treated with said signal by means of a transducer, is administered, in particular under the tongue. - transmitter. The present invention also relates to a system for producing a signal, in particular an electrical or electromagnetic signal, having a coagulant or anticoagulant effect, from a source substance having a coagulant effect, in particular Ca ++ ions, or anticoagulant, in particular of the heparin. Said system comprises a transducer-receiver receiving the electromagnetic field from said source substance, said transducer-receiver transforming said electromagnetic field into a

  signal, including an electrical signal.

  Preferably, the system according to the invention further comprises a transmitter generating an excitation field of electrical, magnetic and / or

  electromagnetic in an area where said source substance is located.

  Said transducer-receiver, receiving the fields resulting from the interaction of said excitation field and said source substance, transforms said resulting fields into a signal, in particular a signal

electric.

  Preferably also, the system according to the invention further comprises control means for controlling the correlations between on the one hand, the signal coming from said transducer-receiver and on the other hand, the coagulant or anticoagulant activity of said source substance . Said control means comprise a transducer-transmitter applying, directly or indirectly, said signal to a biological control system. Said control means further comprise verification means for verifying that the biological control system reacts in accordance with the coagulant or anticoagulant activity of the source substance of which is

2783606

issued the signal.

  Advantageously, the biological control system is blood or

  plasma to which said signal is applied by means of said transducer-

  transmitter. Lich plasma in platelets can also be advantageously used. Advantageously, in another alternative embodiment, the biological control system is an animal, in particular a rabbit, to which a substance, in particular water, is administered, in particular under the tongue,

  processed by said signal by means of said transducer-transmitter.

  Signal according to the invention having a coagulant or anticoagulant effect The present invention also relates to a signal proper, notably an electric or electromnagnetic signal, having a coagulant or anticoagulant effect. Said signal is obtained from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, by implementing the methods or the systems described above. Said signal is characterized in that a biological control system reacts, after direct or indirect application of said signal, in accordance with the coagulating activity or

  anticoagulant of the source substance from which the signal comes.

  Advantageously, the biological control system is blood or

  plasma to which said signal is applied by means of a transducer-

  transmitter. One can also advantageously use plasma rich in platelets. Advantageously in another alternative embodiment, the biological control system is an animal, in particular a rabbit, to which a substance is administered, in particular under the tongue, in particular water,

  processed by said signal by means of a transducer-transmitter.

  The invention also relates to the therapeutic applications of such a signal. The signal according to the invention can be used, directly or

9 2783606

  indirectly through a receptor material, in the treatment of thromboembolic diseases. I can also be used, directly or indirectly via a receiving material,

  to perform coagulation exploration tests.

  Method according to the invention for testing the coagulant or anticoagulant effect of a signal The invention also relates to a method for testing a signal having a coagulant or anticoagulant effect. Said signal is obtained from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, by implementing the methods or systems previously described. The method according to the invention comprises the step of applying said signal, directly or indirectly, to a biological test system and of verifying that the biological test system reacts in accordance with the coagulant or anticoagulant activity of the

  source substance from which the signal is derived.

  Advantageously, the biological test system is blood or plasma to which said signal is applied by means of a transducer-transmitter. We

  can also advantageously use platelet rich plasma.

  Advantageously, according to another alternative embodiment, the biological test system is an animal, in particular a rabbit, to which is administered, in particular under the tongue, a substance, in particular water, treated with

  said signal by means of a transducer-transmitter.

  The method according to the invention for testing the coagulant or anticoagulant effect of a signal can be applied to the control of product production

homeopathic.

  Other characteristics and advantages of the invention will become apparent on

  reading of the description of variant embodiments of the invention, given

  by way of an indicative and nonlimiting example, as well as by reading the examples of experiments having succeeded in validating the process of production of a substance or of a characteristic electrical signal, having effects

  coagulants or anticoagulants. The description refers to the accompanying drawings

  in which - FIG. 1 shows a diagram of an exemplary embodiment of a system allowing to produce a characteristic electrical signal, and to apply the characteristic electrical signal thus produced to a receptor substance or to a biological control system or to a sensitive biological system, - figure la represents a detailed perspective view of a patch of the device for producing the electrical signal, showing the excitation field transmitter and the transducer-receiver receiving the resulting fields, - figure lb represents in block diagram form the type of microcomputer used either to generate the excitation fields, or to record and transmit in digitized form the characteristic electrical signal, - Figure lc represents a detailed perspective view of a patile of a transducer-transmitter intended to apply the characteristic electrical signal to a receptive substance e or to a biological system of

  control or to a sensitive biological system.

  General diagram of the system We will now describe, with reference to FIGS. 1, 1a, 1b and 1c, an exemplary embodiment of a system allowing (i) to produce - from Ca ++ ions a characteristic electrical signal having an effect coagulants, or - from heparin a characteristic electrical signal having an anticoagulant effect and, (ii) applying such a characteristic signal to a receptor substance or to a biological control system or to a system

sensitive biological.

  The system comprises a device 10 for producing an electrical signal characteristic of the biological and / or chemical activity or of the biological and / or chemical behavior of a substance 1 or of an active element contained in said substance. In the case of the variant described with reference to Figures 1, la, lb and lc, said substance I is either Ca "+ ions in solution at lpM in water for injection (eg Biosédra brand) - either heparin at a concentration of 2.5 IU / ml in the same

water quality.

  Device 10, located in Paris for example, produces an electrical signal

  characteristic which is digitized after analog-digital conversion.

  The signal thus digitized is, in a manner known per se, transmitted remotely, for example by a computer communication network of the internet type using radio links 11. The signal thus digitized

  transmitted is received by an applicator 12, located in New York for example.

  The applicator 12 comprises transmission means 13. The transmission means 13 allow the characteristic signal to be applied (after digital-analog conversion) to a receiving substance or to a

  biological control system or a sensitive biological system.

  The means provided for digitizing and transmitting remotely the electrical signal characteristic of the Ca "+ ion or of heparin are not essential to the realization of the invention. They have been described to demonstrate the technical and commercial advantages linked to the possibility of producing an electrical signal characteristic of the Ca ++ ion or heparin having, like the source substances from which they originate,

  coagulant or anticoagulant effects.

  In the case of the variant described with reference to FIGS. 1, la, lb and lc,

12 9 2 783 606

  - the receiving substance is water or a water-ethanol mixture or homeopathic granules, - the biological control system or the biological system

sensitive is blood or plasma.

  I The device for producing the signal characteristic of the Ca ++ ion or heparin - The enclosure The device for producing the signal 10 comprises an enclosure D, 2 provided with an electrical and magnetic shielding isolating it from the parasitic fields originating of the environment. The shielded cylindrical enclosure is composed of three superimposed layers: copper, soft iron, murnetal, made of sheet metal 1 mm thick. The enclosure has an internal diameter of mm and a height of 100 mnit The enclosure is closed by a shielded cover 5. In enclosure 2 is placed a curve 3 in glass or plastic having the dimension of 10 mln x 10 min x 45 mins. This tank 3 contains 1 niml of the substance 1. That is to say either Ca '+ ions in solution at lpM in water for injection (eg Biosédra brand), or heparin at the concentration of 2.5 IU / mnl in the same

water quality.

  * The transmitter of the specific excitation field A transmitter 4 is located inside the enclosure. It generates a specific excitation field of an electromagnetic nature. The transmitter is powered by a generator 14. The transmitter 4 comprises a coil advantageously supplemented by a soft iron magnetic core. The emitting coil 4 has an impedance of 300 ohms, an inside diameter of 6 min, an outside diameter of 16 mrn, a length of 6 nmn. The soft iron magnetic core is placed in contact with the outer walls of the tank 3. Said substance 1 is thus subjected to the excitation field emitted

1 3 2783606

  by the transmitter 4. The generator 14 is designed to generate a low frequency signal in particular low frequency canine or sinusoidal signals, pink noise or, advantageously, white noise. The spectrum of the excitation signal supplying the transmitting coil 4 corresponds substantially to the spectrum of audible frequencies (20 Hz - 20,000 Hz). The generator 14 may be an analog signal generator of known type, using for example a read only memory (ROM, PROM, EPROM, EEPROM in

  Anglo-Saxon tenninology) containing the digital signal of the desired noise.

  This memory is connected in a manner known per se to a digital-analog converter. One can also use a microcomputer 14, provided

  a sound card 25 comprising a digital-analog converter 41.

  One can for example use a computer 14 of the PC type, operating under the operating system WINDOWSx 95 of the company MICROSOFT and comprising, in addition to the sound card 25 a microprocessor 27, an input / output interface 29, a controller 31 d 'a mass memory 33 and a video interface 35 connected by one or more buses 37. The digital analog converter 41 of the sound card 25 has an output terminal 8. The output terminal 8 of the sound card of the microcomputer 14 is connected to the input terminal 8 'of the transmitter 4, via an amplifier 15 whose characteristics are the following: bandwidth from 10 Hz to 20 kHz, gain 1 to 10, input sensitivity +/- 1 V Among the 25 sound cards that can be used, we can cite for example the Soundblaster 16 card sold by

CREATIVE LABS.

  * The transducer-receiver The transducer-receiver 6, located inside the enclosure 2, receives the fields resulting from the interaction of said specific excitation field and said substance 1. The transducer-receiver 6 transfers said fields resulting in an electrical signal. This electrical signal is present, at the output terminals 9 ′ of the transducer-receiver 6, in the form of a

14 2783606

  difference of variable potential or of an electric current of variable intensity. The transducer-receiver 6 comprises a coil having a soft iron core. This coil has an impedance of 300 ohms, an inside diameter of 6 nmn, an outside diameter of 16 rmmn, a length of 6 min. The soft iron magnetic core is placed in contact with the walls

tank exterior 3.

  Advantageously, the characteristic electrical signal available at the output

  of the transducer-receiver 6 is amplified by an amplifier-

  preamplifier 16. The amplifier-preamplifier 16 has the following characteristics: bandwidth from 10 Hz to 20 kHz, gain 10 to

, input sensitivity +/- 100 mV.

  In the case of the variant embodiment described with reference to FIGS. 1, 1a, 1b, 1c, an emitter 4 of excitation field is provided. The use of such a transmitter 4 promotes the production of an electrical signal characteristic of the Ca ++ ion or heparin. However, it is also possible to capture, by means of a transducer-receptor 6, a signal characteristic of the Ca ++ ion or of heparin, without implementing a

  excitation field and without using a shielded enclosure.

  The recording of the characteristic electrical signal * * Analog recording The recording of the characteristic electrical signal, or that of the electrical signal which derives therefrom after amplification or processing, can be carried out in analog by a signal recorder, in particular on magnetic tape, frequencies of the characteristic electrical signal at the output of the transducer-receiver 6. Since the bandwidth used corresponds to the audio band, it is possible in particular to use a tape recorder. The output terminal 9 'of the transducer-receiver 6 is connected to the microphone input or to the line input of such a tape recorder. During reading, the recorded characteristic electrical signal is collected at an output terminal, in particular at the line output or at the speaker output of the tape recorder. * Digital recording Preferably, a digital recording of the characteristic electrical signal is carried out after analog-digital conversion of said signal. For this purpose, a microcomputer 17 is used, provided with a signal acquisition card 25. The microcomputer 17 further comprises a microprocessor 27, an input / output interface 29, a controller 31 of a mass memory 33 and a video interface 35 connected by one or more buses 37. It is possible, for example, to use a PC type computer 17, operating under the operating system X \ fNTDOWS '95 from the company MICROSOFT This microcomputer may be of the same type as that used to generate the excitation field. It can be the same microcomputer. The output 9 'of the transducer-receiver 6 or of the amplifier-preamplifier 16 is connected to the input 9 of the analog-digital converter 39 of the

  card 25 of computer 17. Preferably, the analog converter

  digital 39 has a resolution higher than 12 bits. It is advantageously equal to 16 bits. Also preferably, the analog-digital converter 39 has a sampling frequency twice the

  maximum frequency that you want to be able to digitize, for example 44 kHz.

  An acquisition of a characteristic electrical signal is carried out for a duration for example of between I and 60 s (for example 6 sec) and the digital file is recorded in a mass memory 33, for example

  in the form of a sound file in WAV format.

  All connections are made with shielded cable. All devices are switched on

to ground.

  * Processing of the characteristic electrical signal For the processing of the characteristic electrical signal or of the signal derived therefrom, the Matlab software from the company "The

16 2783606

  MathWorks ". The digital file, saved as described above, may optionally undergo digital processing, such as digital amplification for signal level calibration, filtering to eliminate unwanted frequencies, or be transferred into its spectrum by a discrete FOURIER transform, preferably by the fast FOURIER transform algorithm (FTI in Anglo-Saxon ternninology) .The duration of the signal produced can be increased by

  repeating in a file several times a fiagmient or the entire file-

his product originally.

  Means for processing the characteristic electrical signal can be

  used to improve the performance of the characteristic electrical signal.

  In the case of a first alternative embodiment, a second transducer-receiver of the same type is provided as that previously described. In the absence of said substance, this second transducer-receiver transforms the excitation field into an electrical signal. This electrical signal is subtracted by a series connection opposite to the signal from the first transducer-receiver. This gives a characteristic electrical signal more representative of the interaction of the excitation field.

specific and substance.

  In the case of a second variant embodiment, the processing means take into account the characteristics of the specific excitation field and reprocess the characteristic electrical signal in the following manner. We first of all calculate the distribution of the spectral power (PSD). Then we truncate this spectral power while keeping only the frequency band going for example from 140 Hz to 14 kHz, we reconstitute a signal from this spectral power and neutral phases, for example randomly generated, finally we calibrate the power of the signal thus produced. By neutral phases, we mean

17 2783606

  phases not originating from a source substance exhibiting biological activity. In the case of the variant embodiment described with reference to FIGS. 1, 1a, 1b, 1c, provision is made to digitize, record and process the characteristic electrical signal before applying it to a receiving substance

  or a biological control system or a sensitive biological system.

  These operations are not essential for the exploitation of the electrical signal characteristic of the Ca ++ ion or of heparin, even if they

promote implementation.

  The characteristic electrical signal available at the transducer output-

  receiver 6 and if necessary of the preamplifier 16 already constitutes in itself a product capable of industrial applications. We will come below for which applications it can be implemented in particular by means of an applicator 12 making it possible to apply them to a receptor substance or to

  a biological control system or a sensitive biological system.

  He. Remote transmission of the characteristic electrical signal The file of the characteristic electrical signal of the Ca + "ion or of heparin, recorded in the digital form colmune it has just been described, possibly after processing, can be transferred remotely by a network of This network can include radio links 11. The file of the electrical signal characteristic of the Ca ++ ion or of heparin, thus transmitted, is recorded by the memory of the mass of a microcomputer 18. We can by example use a PC type computer, operating under the operating system WINDOWS '95 from the company MICROSOFT. This microcomputer 18 can be of the same type as that used to generate the excitation field. The file of the characteristic electrical signal digitized, thus recorded by the remote microcomputer 18, can be used, in a manner known per se, to produce an electrical signal because analog file The file, possibly processed, is transformed by a digital-analog converter 41 of the card 25 (or of a separate card) of the computer 18. The digital-analog converter 41 delivers on its output 8 an electrical signal analog characteristic of the biological activity of the Ca ++ ion or of the heparin from which it is derived. This analog electrical signal can be transformed, as will be described below, into an electromagnetic field and applied to a receptor substance or to a biological system of

  control or to a sensitive biological system.

  Im. The applicator of the signal characteristic of the ion Ca 'or of heparin We will now describe, with reference to FIG. 1c, an exemplary embodiment of a system allowing the application of the electrical signal characteristic of the ion Ca ++ or heparin to a biological system

  receptor and modify its chemical behavior.

  The container 50 contains the receptor biological system. In the case of the variant described with reference to Figures 1, la, lb and Ic, the container 50 contains:

  - a receiving substance such as water or a water mixture -

  ethanol or homeopathic granules, or - a biological control system or a biological system

sensitive like blood or plasma.

  The container 50 is placed in an electromagnetic field radiated by a transducer-transmitter 51, typically a coil. The coil has for example a length of 80 nmm, an inside diameter of 50 mni, an outside diameter of 55 mrn. It has 300 turns of a wire with a diameter of 0.5 mm. Its impedance is 4 ohms. The coil 51 is connected to ground. Without this representing any limiting character, the coil 51 of the transducer-transmitter has a vertical axis allowing the introduction of the container 50 containing the receiving biological system. Terminals

19 2783606

  input 8 ′ of this coil 51 are connected, in the case of the variant embodiment described, to output 8 of the analog-digital converter 41 of the microcomputer 18 via an amplifier 19 having the following characteristics: bandwidth of 10 Hz to 20 kHz, gain I to 20, input sensitivity 250 mnV, RMS 60W output power at 8 ohms, signal to noise ratio 80 dB. The voltage across the coil 51 has an amplitude of 10 Volts rms and the signal is applied for 10 min. The input terminals 8 ′ of the applicator can also be, in the case of certain variants, directly connected to the output of the preamplifier 16 or to the output 8 of the digital-analog converter

41 from computer 17.

  Experiments In order to illustrate an alternative embodiment, - of a method and a system according to the invention for producing a substance having a coagulant or anticoagulant effect, - of a substance according to the invention having a coagulant or anticoagulant effect , - a method according to the invention for testing the coagulant or anticoagulant effect of a substance and its application to the production of homeopathic products, - a method and a system according to the invention for producing a signal having a coagulant or anticoagulant effect, - of a signal according to the invention having a coagulant or anticoagulant effect - of a method according to the invention for testing the coagulant / anticoagulant effect of a signal and of its application to the production of homeopathic products,

  the following experiments were carried out.

  Reminder of the effects of heparin and Ca 'ions on the coagulation of human or rabbit plasma Heparin (25,000 IU / 5 ml, Choay Laboratory, Sanofi Wintlhrop) is an anticoagulant acting by inhibiting the transformation of prothrombin into thrombin. At the site of action, the effect of heparin is immediate. It acts through a natural inhibitor called

cofactor, or antithrombin III.

  Protamine sulphate (10,000 IU / 10 ml, Choay Laboratory, Sanofi Winthrop) forms a salt with heparin and causes a unit for unit suppression of its anticoagulant effect. 1 ml protamine solution

  neutralizes the anticoagulant activity of 1000 units of heparin.

  The calcium ion Ca 'is an ion essential for coagulation.

  Source substances and materials used The characteristic electrical signals were recorded from I ml samples of the following solutions - Ca ++ in lIM solution in water for injection (for example from Biosédra) - Mg ++ in 1lpM solution in the same water quality, - heparin in solution at a concentration of 2.5 IU / ml in the same water quality, - heparin + protamine complex (respectively 2.5 IU / ml and

  0.025 mg / ml), in solution in the same quality of water.

  The equipment used has been described with reference to Figures la, lb, lc. The transducer-receiver 6 has the characteristics described. The transducer-transmitter 51, permitting to apply the characteristic electrical signal to a receiving substance or to a biological control system or to a sensitive biological system, is an electromagnetic coil having the following characteristics - length: 80 mm, - inside diameter: 50 mmn, - number of turns: 300 turns,

- impedance: 4 ohms.

  A coagulation evaluation was made using the following notation: - significant coagulation: 2 - moderate coagulation: 1 - no coagulation: 0 Protocol n l. "In vitro" experiment: Coagulant or anticoagulant action of characteristic electrical signals on Plasma

Rich in Platelets (PRP).

  The purpose of this protocol is to demonstrate that - on the one hand, the method and the system described make it possible to produce an electrical signal characteristic of the Ca ++ ion and of heparin having respectively a coagulant or anticoagulant effect, and - d on the other hand, the method and the system described make it possible to test an electrical signal having respectively a coagulant or anticoagulant effect. As a biological control system for revealing the electrical signal characteristic of the Ca 'ion and heparin, or as a sensitive biological system for testing the coagulant or anticoagulant effect

  of an electrical signal, rabbit (or human) plasma is used.

  The blood of a "New, -Zealand White" rabbit is taken from the artery of the ear and collected on an ACD anticoagulant (9 vol. Blood / I vol. ACD), the composition of which is as follows: citric acid 0.8 %, sodium citrate 2.2%,

anhydrous glucose 2.23%.

  After centrifugation (180 g, 15 minutes) at room temperature, the blood is divided into 3 layers: from top to bottom, the Plasma Rich Plasma (PRP), the buffy coat and the pellet of red blood cells. The PRP is taken at

the pipette by gentle suction.

  Anticoagulant effect of a signal, anticoagulant effect of the electrical signal characteristic of heparin ml of PRP are placed in a tube 50 in the center of an electromagnetic coil 51 to be exposed to the signal applied for 10 nm with a voltage of 10V across the terminals of the coil.

  1 ml samples of PRP thus treated are placed in four tubes.

  20 μl of Ca "(50, 100, 150 and 200 mM) are delivered into each tube to obtain final concentrations of calcium in the PRP of (1, 2, 3 and 4

  mM). Then incubate for 15 to 20 minutes.

  The results obtained are presented in the table below Evaluation of the Signalless Coagulation signal after application Heparin Complex of 20 min of the Signal Heparin + protamine Concentration Avg _ 1 SD (n) Avg 1 SD (n) Avg 1 SD (n ) in Ca ++ (maM)

  1_ _ 0.00 + 0.00 (5) 0.18 + 0.50 (22) 0.42 0.74 (21)

  2 0.75 + 0.88 (8) 0.25 + 0.53 (24) 1.25 0.94 (24)

  3 1.75 _ 0.70 (8) 0.54 + 0.65 (24) 1.91 0.40 (24)

  4 1.75 0.70 (8) 1.41 0.88 (24) 1.91 0.40 (24)

  n: number of values; Avg: average; SD: standard deviation We observe that an application of the heparin signal has an effect of inhibiting the coagulation of PRP. Under the same conditions, PRP not exposed to a signal or PRP exposed to a control signal, like for example that of the heparin + protamine complex, does not exhibit an inhibiting effect. This coagulation inhibiting effect is particularly notable for a Ca ++ concentration of between 2

and 3 mM.

  Thus, the biological control system constituted by platelet-rich plasma can control that the characteristic signal of

  heparin has an anticoagulant effect.

  Thus, the sensitive biological system constituted by plasma rich in platelets makes it possible to test whether a characteristic signal has an anticoagulant effect. Coagulating effect of a signal, coagulating effect of the electrical signal characteristic of the calcium ion (Ca ++) 1 ml of PRP is placed in a tube in the center of an electromagnetic coil to be exposed to the applied signal for 10 min

  with a voltage of 10 V across the coil.

  The results obtained are presented in the table below Without application Signal Signal Signal Calcium Ca ++ Magnesium Mg ++ Avg + I SD (n) Avg + ISD (n) Avg 1 SD (n) Assessment of coagulation at 0.00 + 0.00 (7) 1.57 + 0.75 0.00 + 0.00 (14) after 60 min (14) Average time of no retraction no retraction retraction observed after <12h (14) observed after 24h (7) of 24h (14) Interpretation We observe that an application of the calcium signal Ca ++ has a

  coagulation of PRP comparable to that of calcium Ca ++ proper.

  It is observed that an application of the signal of magnesium Mg ++ does not induce

no coagulation effect of PRP.

  Thus, the biological control system constituted by plasma rich in platelets makes it possible to control that the characteristic signal of calcium

Ca ++ has a coagulating effect.

  So therefore, the sensitive biological system consisting of plasma rich in

  platelets to test whether a characteristic signal has a coagulating effect.

  Protocol No. 2. "In Vivo" Experience: Coagulating Action or

  anticoagulant of characteristic electrical signals.

  The purpose of this protocol is to demonstrate that: - on the one hand, the method and system described allow * to produce an electrical signal characteristic of the Ca ++ ion and heparin, and * to apply this electrical signal to a receptor substance having after treatment respectively a coagulating or anticoagulant effect, and on the other hand, the method and the system described allow testing

  a substance having respectively a coagulant or anticoagulant effect.

  As a biological control system making it possible to reveal the coagulating or anticoagulant effect of the treated substance, or as a sensitive biological system making it possible to test the coagulating or anticoagulant effect of a substance, a rabbit is administered which is administered, sublingually, treated water by means of a characteristic electrical signal

of the source substance.

  The water used is water for Biosédra injection.

10 mi bulbs.

  1. The water (10 ml) is placed in a tube 50 in the center of an electromagnetic coil 51. The water is exposed to the characteristic signal considered for 10 nm with a voltage across the coil. V. 2. On then stir the water for 15 seconds at the maximum speed of the vortex. 3. The rabbit is administered sublingually 1 ml of the water thus treated with

  the characteristic signal considered.

  Blood samples (1 ml) are taken from glass tubes in the artery of the ear, before administration, then 1, 5, 10, 15 and 30 minutes after.

administration of treated water.

  The results obtained are presented in the table below. Assessment of coagulation Signal Signal Complex Heparin Heparin + protamine Collection time Avg + ISD (n) Avg + 1SD (n) before administration 2.0 + 0.0 (3) 2.0 + 0.0 (3 ) 1 min 0.0 + 0.0 (6) 2.0 0.0 (6) hand 1. 33 _ 1.03 (6) 2.0 0.0 (6) hand 1.33 1.03 (6) 2.0 0.0 (6) min 1.42 + 0.97 (7) 2.0 0.0 (6 ) main 2.00 + 0.00 (7) 2.0 0.0 (6) Interpretation It is observed that administration of water treated by the characteristic signal of heparin has an inhibiting effect on blood coagulation for fifteen minutes. On the other hand, an administration of water treated by the signal

  of the heparin + protamine complex has no inhibiting effect.

  Thus, the biological control system constituted by an animal allows to control that a receiving substance processed by the signal

  characteristic of heparin, especially water, has an anticoagulant effect.

  Thus, the sensitive biological system constituted by an aninal makes it possible to test, by controlling the characteristic signal of a substance (for example the heparin + protamine complex), if this substance has a

* coagulant or anticoagulant effect.

  It is thus thus established that one can control the production of homeopathic products by the use of substances with known effect (like heparin) and by controlling that the homeopathic products (granules, solutions, ...) from this substance also have, at the end of the chain, the corresponding activity (in the example described, the anticoagulation activity). The characteristic signal of a drug or a receptor substance treated by the characteristic signal of a drug has the same effects

  signal source drug considered.

  Likewise, similar anticoagulant effects are obtained with hirudin on rabbit or human blood or plasma. Signals from hirudin have a stronger anticoagulant effect

than those from heparin.

  The results obtained with hirudin and rabbit blood will be found below: Evaluation of coagulation at Signal Signal after 20 min Hirudin Water Concentration in Ca2 + (mMNI) raw data raw data

2 0.0 0.0

3 0.0 2.2

[_ _ _ _ __4 [0.1 2.2

  The results obtained with hirudin and human blood are given below: Evaluation of coagulation Signal Signal Ca2 +: 7.5 mM Hirudin Water Time (min) raw data raw data

0.0 0.0

0.0 1.2

1.1 2.2

2.2 2.2

2.2 2.2

lh 2.2 2.2

Claims (21)

Claims   1. Method for producing a substance having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, said method comprising the steps: - of transforming the electromagnetic field from said source substance, into a signal, in particular an electrical signal, by means of a transducer-receiver capturing said electromagnetic field, - applying to a receiving substance, in particular water or a water-ethanol mixture or homeopathic granules, said signal   from said transducer-receiver, by means of a transducer-   transmitter, (so that after the above-defined treatment, the receptor substance, initially inactive, exhibits coagulating or anticoagulant activity; said receptor substance thus treated being below called the "treated substance").   2. Method according to claim 1, such as for transforming the electromagnetic field coming from said source substance into an electrical signal: - placing said source substance in an area subjected to an excitation field of electrical, magnetic and / or electromagnetic nature, - the fields resulting from the interaction of the excitation field and said source substance are transformed into an electrical signal, at   by means of a transducer-receiver capturing said resulting fields.   3. System for producing a substance having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, said system comprising: - a receiving transducer-receptor the electromagnetic field coming from said source substance, said transducer-receiver transforming said electromagnetic field into a signal, in particular an electrical signal, - a transducer-transmitter for applying said signal coming from said transducer-receiver to a receiving substance, in particular water or a water-ethanol mixture or homeopathic granules, (so that after the treatment defined above, the receptor substance, initially inactive, exhibits coagulant or anticoagulant activity; said receptor substance thus treated being below called the "treated substance").   4. System according to claim 3 such that it further comprises: - a transmitter generating an excitation field of electrical, magnetic and / or electromagnetic nature in an area where said source substance, said transducer-receiver, receiving the fields resulting from the interaction of said excitation field and said source substance, transforming said   fields resulting in a signal, in particular an electrical signal.   5. Substance having a coagulating or anticoagulant effect, said substance possibly being in particular water or a water-ethanol mixture or homeopathic granules, and - having been treated by means of an electrical or electromagnetic signal originating from a source substance having coagulant effects, in particular Ca + ions, or anticoagulants, in particular of Heparin.   6. Use of the substance according to claim 5 for the production of a medicament intended for the treatment of thromboembolic disease,   or exploring coagulation.   7. Method for testing a substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, said method comprising the steps: - of transforming the electromagnetic field originating from said substance, into a signal, in particular a signal electric, by means of a transducer-receiver capturing said electromagnetic field, - applying to a sensitive biological system, directly or   indirectly, said signal from said transducer-receiver.   8. The method as claimed in claim 7, such as for transforming the electromagnetic field originating from said substance into an electrical signal: said substance is placed in an area subjected to an excitation field of an electrical, magnetic and / or electromagnetic nature, - it is transformed the fields resulting from the interaction of the excitation field and said source substance in an electrical signal, at the   by means of a transducer-receiver capturing said resulting fields.   9. Method according to any one of claims 7 or 8, such as   sensitive biological system is blood or plasma to which one applies   said signal by means of a transducer-transmitter.   10. Application of the method according to any one of claims 7 to   9 to control the production of homeopathic products.   11. Method for producing a signal, in particular an electrical or electromagnetic signal, having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, said method comprising the steps: - of transforming the electromagnetic field originating from said source substance, into a signal, in particular an electrical signal, by means of a transducer-receiver sensing said electromagnetic field, 12. The method as claimed in claim 11, such as for transforming the electromagnetic field originating from said source substance into an electrical signal: - placing said source substance in an area subjected to an excitation field of an electrical, magnetic and / or electromagnetic nature, - The fields resulting from the interaction of the excitation field and the source substance are transformed into a signal, in particular an electrical signal, by means of a transducer-receiver capturing said resulting fields.   13. Method according to any one of claims 11 or 12,   further comprising the step: - of checking the correlations between on the one hand, the signal coming from said transducer-receiver and on the other hand, the coagulating or anticoagulant activity of said source substance, by applying, directly or indirectly, said signal to a biological control system and verifying that said biological control system reacts in accordance with the coagulant or anticoagulant activity of the source substance of which is issued the signal.   14. The method of claim 13, such that the biological control system is blood or plasma to which said signal is applied to by means of a transducer-transmitter.   15. System for producing a signal, in particular an electrical or electromagnetic signal, having a coagulating or anticoagulant effect, from a source substance having a coagulating effect, in particular Ca ++ ions, or anticoagulant, in particular heparin, said system comprises a transducer-receiver receiving the electromagnetic field originating from said source substance, said transducer-receiver transforming said electromagnetic field into a signal, in particular an electrical signal, 16. The system as claimed in claim 15, as further comprising: - a transmitter generating an excitation field of electrical, magnetic and / or electromagnetic nature in an area where said source substance, said transducer-receiver, receiving the fields resulting from the interaction of said excitation field and said source substance, transforming said   fields resulting in a signal, in particular an electrical signal.   17. System according to any one of claims 15 or 16,   further comprising: - control means for controlling the correlations between on the one hand, the signal coming from said transducer-receiver and on the other hand, the coagulating or anticoagulant activity of said source substance, said control means comprising a transducer -emitter applying, directly or indirectly, said signal to a biological control system, said control means further comprising verification means for verifying that the biological control system reacts in accordance with the coagulant or anticoagulant activity of the source substance, East issued the signal.   18. The system as claimed in claim 17, such that the biological control system is blood or plasma to which said signal is applied to using said transducer-transmitter.   19. Method for testing a signal having a coagulant or anticoagulant effect, said signal being obtained by means of the method according to any one of   claims 11 to 14 or by means of the system according to any one   claims 15 to 18 from a source substance having an effect   coagulant, in particular Ca + ions, or anticoagulant, in particular heparin, said method comprising the step of applying said signal, directly or indirectly, to a test biological system and of verifying that the test biological system reacts in accordance with coagulating activity or   anticoagulant of the source substance from which the signal comes.   20. The method of claim 19, such that the test biological system is blood or plasma to which said signal is applied by means of a transducer-transmitter.   21. Application of the method according to any one of claims 19   or 20 to control the production of homeopathic products.